Cover Image
市場調查報告書

病毒性結膜炎開發平台藥物市場: (FST-100及APD-209) 產業分析,開發平台評估,專利分析,2020∼2023年的預測

Viral Conjunctivitis Pipeline Drugs Market: (FST-100 and APD-209): Industry Analysis, Pipeline Review, Patent Analysis, and Forecast 2020 - 2023

出版商 Transparency Market Research 商品編碼 364443
出版日期 內容資訊 英文 70 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
病毒性結膜炎開發平台藥物市場: (FST-100及APD-209) 產業分析,開發平台評估,專利分析,2020∼2023年的預測 Viral Conjunctivitis Pipeline Drugs Market: (FST-100 and APD-209): Industry Analysis, Pipeline Review, Patent Analysis, and Forecast 2020 - 2023
出版日期: 2016年06月14日 內容資訊: 英文 70 Pages
簡介
病毒性結膜炎開發平台藥物市場,英國、美國、德國、澳洲、日本、巴西為主要市場,考慮持續中臨床實驗的話,美國今後數年,獨佔市場。預計美國的病毒性結膜炎開發平台藥物市場,以2020∼2023一年更新架年複合成長率46.5%擴大。

本報告提供全球病毒性結膜炎開發平台藥物市場相關調查,市場現狀及未來發展預測,各設備,各地區趨勢,及參與企業簡介彙整。

第1章 序論

第2章 摘要整理

第3章 產業分析

  • 簡介
    • 徵兆與症狀
    • 診斷
    • 管理
  • 市場趨勢
    • 推動市場的要素
      • 龐大的未滿足需求
      • 堅固的開發平台
    • 阻礙要素
      • 低的診斷率
      • 自我限制
    • 機會
      • 投資到嚴格的研究開發活動
    • 商品化活動的強化
  • 流行病學環境
  • 開發平台藥物的專利分析

第4章 各開發平台藥物市場

  • 簡介
  • FST-100
  • APD-209
  • 早期臨床試驗前

第5章 市場區隔:各國

  • 簡介
  • 美國
  • 英國
  • 德國
  • 澳洲
  • 日本
  • 巴西

第6章 建議

第7章 企業簡介

  • Adenovir Pharma AB
  • Allergan plc
  • NanoViricides, Inc.
  • Shire plc
  • NovaBay Pharmaceuticals, Inc.
  • Novartis AG
  • Panoptes Pharma GES.M.B.H.
  • NicOx S.A.

圖表

目錄

Viral conjunctivitis therapeutics is undergoing a transitional phase. Currently, there is no drug available for the treatment of viral conjunctivitis. However, the presence of a robust pipeline indicates towards a thriving future. The global market for viral conjunctivitis pipeline drugs is likely to exhibit a thumping CAGR of 69.60% between 2020 and 2023 and reach an opportunity worth US$462.4 mn by the end of the forecast period.

The increasing investments from ophthalmic drug manufacturers for the development of efficient treatment for viral conjunctivitis, coupled with the increasing awareness among people and augmenting expenditure on healthcare, are accelerating the growth rate of this market significantly.

On the other hand, lower diagnosis rate of viral conjunctivitis is decreasing the patient pool for the treatment, causing major hindrance in the market's growth.

Pipeline Drugs in U.S. Gain Momentum from Promising Results of Ongoing Clinical Trials

The U.K., the U.S., Germany, Australia, Japan, and Brazil are the key regional markets for viral conjunctivitis pipeline drugs. Considering the ongoing clinical trials, the U.S. is likely to occupy the leading position among these in the coming years. The major factors driving the growth in this market are promising results of the ongoing clinical trials, the increasing awareness regarding eye care among patients and medical professionals, the high cost of the drugs, and the availability of viral conjunctivitis diagnostic tests.

The U.S. market for viral conjunctivitis pipeline drugs is projected to report a CAGR of 46.50% during the period from 2020 to 2023.

APD-209 to Exceed FST-100 by 2023

APD-209 and FST-100 are the main viral conjunctivitis drugs in the pipeline. Among the two, FST-100 is projected to hold the largest share in the market by 2020. Foresight Biotherapeutics Inc. initiated the development of FST-100; however, the company was acquired by Shire Plc. in the midway. In May 2014, the drug completed its phase II clinical trial successfully and is expected to enter the phase III of clinical trials in 2016.

Presently, the APD-209 is witnessing moderate rise; however, in the coming years, it will report a higher demand than FST-100. The drug, being developed by Adenovir Pharma AB, is in its second phase of clinical trial. It is likely to enter the third phase by mid-2016.

The market for FST-100 is projected to rise at a CAGR of 27.40% between 2020 and 2023 while the APD-209 market is likely to report a CAGR of 55.0% during the same period.

Leading Players Focus on Research Activities Thanks to Escalating Demand for Targeted Drugs for Viral Conjunctivitis

On the forefront of the global viral conjunctivitis pipeline drugs market are Panoptes Pharma GES.M.B.H., Shire Plc., Allergan Plc, Novartis AG, NovaBay Pharmaceuticals Inc., Adenovir Pharma AB, NicOx S.A., and NanoViricides Inc. As the demand for targeted drugs for viral conjunctivitis is rising, leading enterprises are focusing aggressively on research activities for the development of efficient treatments as well as diagnostic tests for viral conjunctivitis. New entrants in this market are recommended to enhance their distribution networks through strategic partnerships and alliances with local distributors.

Table of Contents

1. Preface

  • 1.1. Report Description
  • 1.2. Research Methodology
  • 1.3. Assumptions
  • 1.4. Market Segmentation

2. Executive Summary

  • 2.1. Viral Conjunctivitis Pipeline Drugs Market Share, by Geography, (Value %), 2023
  • 2.2. Viral Conjunctivitis Pipeline Drugs Market: Market Snapshot

3. Viral Conjunctivitis Pipeline Drugs Market - Industry Analysis

  • 3.1. Introduction
    • 3.1.1. Sign and Symptoms
    • 3.1.2. Diagnosis
    • 3.1.3. Management
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers
      • 3.2.1.1. Large Unmet Needs
      • 3.2.1.2. Strong Pipeline
    • 3.2.2. Restraints
      • 3.2.2.1. Low diagnosis rate
      • 3.2.2.2. Self-Limiting Condition
    • 3.2.3. Opportunity
      • 3.2.3.1. Investment in Rigorous R&D Activities
      • 3.2.3.2. Strengthen Commercialization Activities
  • 3.3. Epidemiology
  • 3.4. Patent Analysis of Pipeline Drugs

4. Market Segmentation - By Pipeline Drug

  • 4.1. Introduction
  • 4.2. Market Revenue of FST-100 (SHP-640), 2020-2023, (US$ Mn)
  • 4.3. Market Revenue of APD-209, 2021-2023, (US$ Mn)
  • 4.4. Early Stage Preclinical Trials (Tabular Form)

5. Market Segmentation - By Country

  • 5.1. Introduction
  • 5.2. U.S. Viral Conjunctivitis Pipeline Drugs Market, 2020-2023, (US$ Mn)
  • 5.3. U.K Viral Conjunctivitis Pipeline Drugs Market, 2021-2023, (US$ Mn)
  • 5.4. Germany Viral Conjunctivitis Pipeline Drugs Market, 2021-2023, (US$ Mn)
  • 5.5. Australia Viral Conjunctivitis Pipeline Drugs Market, 2022-2023, (US$ Mn)
  • 5.6. Japan Viral Conjunctivitis Pipeline Drugs Market, 2022-2023, (US$ Mn)
  • 5.7. Brazil Viral Conjunctivitis Pipeline Drugs Market, 2020-2023, (US$ Mn)

6. Recommendations

7. Company Profiles

  • 7.1. Adenovir Pharma AB
  • 7.2. Allergan plc
  • 7.3. NanoViricides, Inc.
  • 7.4. Shire plc
  • 7.5. NovaBay Pharmaceuticals, Inc.
  • 7.6. Novartis AG
  • 7.7. Panoptes Pharma GES.M.B.H.
  • 7.8. NicOx S.A.

List of Figures

  • FIG. 1: Viral Conjunctivitis Pipeline Drugs Market Share, by Geography, (Value %), 2023 (E)
  • FIG. 2: Industry Analysis: Viral Conjunctivitis Pipeline Drugs Market
  • FIG. 3: Viral Conjunctivitis: Signs and Symptoms
  • FIG. 4: Market Revenue of FST-100, (US$ Mn), 2020-2023
  • FIG. 5: Market Revenue of APD-209, (US$ Mn), 2021-2023
  • FIG. 6: U.S. Viral Conjunctivitis Pipeline Drugs Market Revenue, (US$ Mn), 2020-2023
  • FIG. 7: U.K. Market Revenue, (US$ Mn), 2021-2023
  • FIG. 8: Germany Market Revenue, (US$ Mn), 2021-2023
  • FIG. 9: Australia Market Revenue, (US$ Mn), 2022-2023
  • FIG. 10: Japan Market Revenue, (US$ Mn), 2022-2023
  • FIG. 11: Brazil Market Revenue, (US$ Mn), 2020-2023
  • FIG. 12: Allergan Financial Overview: (US$ Mn), 2012-2014
  • FIG. 13: NanoViricides, Inc., Financial Overview: (US$ Mn), 2013-2015
  • FIG. 14: Shire plc, Financial Overview: (US$ Mn), 2013-2015
  • FIG. 15: NovaBay Pharmaceuticals, Inc., Financial Overview: (US$ Mn), 2013-2015
  • FIG. 16: Novartis AG, Financial Overview: (US$ Mn), 2013-2015
  • FIG. 17: NicOx S.A., Financial Overview: (US$ Mn), 2013-2015

List of Tables

  • TABLE 1: Viral Conjunctivitis Pipeline Drugs Market: Market Snapshot
  • TABLE 2: Viral Conjunctivitis: Management
  • TABLE 3: Epidemiology
  • TABLE 4: Patent Analysis of Pipeline Drugs
  • TABLE 5: Viral Conjunctivitis Pipeline Drugs Market Revenue, by Pipeline Drug, (US$ Mn), Expected Launch-2023
  • TABLE 6: Early Stage Preclinical Trials
  • TABLE 7: Viral Conjunctivitis Pipeline Drugs Market Revenue, by Country, (US$ Mn), 2020-2023
Back to Top